The most consistently helpful interventions are the boring ones: structured physical therapy, graded activity, and reducing mechanical aggravators. Injections can help selected pain patterns, but they do not reverse disc degeneration itself .
What tends to help most
Exercise-based rehab: Core stabilization, hip/glute strength, spinal endurance, and movement retraining have the best evidence for improving pain and function over time .
Activity modification: Avoiding repeated end-range flexion/rotation, heavy axial loading when flared, and long static sitting often matters more than any supplement.
Analgesics/anti-inflammatories: These can reduce pain enough to keep rehab moving, but they are symptom tools, not disc-restoring therapies .
Weight and smoking status: Both materially affect disc loading and disc biology. Smoking is especially associated with worse disc outcomes and poorer surgical candidacy .
Sleep and deconditioning reversal: Pain amplification and low spinal endurance feed each other.
Where injections fit
Epidural steroid injections: Best evidence is for radicular pain from nerve root irritation, meaning leg pain, sciatica, numbness, or tingling. Benefit is usually short-term to medium-term, and much weaker for isolated axial back pain without radicular symptoms .
PRP / biologics: Interesting, but still mixed and not standard of care for disc degeneration. The evidence base is much thinner than for rehab, and protocols are heterogeneous .
When surgery enters the picture
Surgery is usually reserved for neurologic deficit, persistent disabling pain despite a real conservative trial, or specific structural problems that correlate with symptoms.
Urgent evaluation matters if there is progressive leg weakness, saddle anesthesia, or bowel/bladder change.
In the peptide lane
For disc degeneration specifically, there is no peptide with strong human evidence showing reliable disc regeneration. Mechanistically, repair-oriented compounds may point in the right direction for inflammation or matrix signaling, but the evidence gap is large and the nearest anchors are mostly animal or soft-tissue data rather than human disc-restoration trials.
If you want, I can narrow this to the pattern that matters most: isolated discogenic back pain vs sciatica/radiculopathy vs neck degeneration, because the evidence changes a lot by phenotype.
Ask your own peptide research questions
Every answer is grounded in peer-reviewed science.